Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Puyuan Xing's publication output changed over time?
ScholarIQpublication output · 2012–2024
Output grew0% over the shown period — from 1 works in 2012 to 1 in 2024.
1
1
2
3
2
1
1
1
20122017201820192020202120222024
What are the most-cited papers on Puyuan Xing?
ScholarIQmost cited works
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Fei Ma, Qiao Li, Shanshan Chen, Wenjie Zhu, Ying Fan, Jiayu Wang, Yang Luo, Puyuan Xing, Bo Lan, Meiying Li, Zongbi Yi, Ruigang Cai, Peng Yuan, Pin Zhang, Qing Li, Binghe Xu
Journal of Clinical Oncology. 2017234 Citations
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
Puyuan Xing, Fan Zhang, Guoqiang Wang, Yu Xu, Chengcheng Li, Shouzheng Wang, Yiying Guo, Shangli Cai, Yan Wang, Junling Li
S2754803477. 2019177 CitationsOPEN ACCESS
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
Jufang Shi, Le Wang, Ning Wu, Junling Li, Zhouguang Hui, Shangmei Liu, Boyan Yang, Shugeng Gao, Jiansong Ren, Huiyao Huang, Juan Zhu, Chengcheng Liu, Jin‐Hu Fan, Shi-Jun Zhao, Puyuan Xing, Ye Zhang, Ning Li, Wendong Lei, Debin Wang, Yunchao Huang, Xianzhen Liao, Xiaojing Xing, Lingbin Du, Li Yang, Yuqin Liu, Yongzhen Zhang, Kai Zhang, You‐Lin Qiao, Jie He, Min Dai
Lung Cancer. 2018134 Citations
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
Yi Ba, Yuankai Shi, Wenqi Jiang, Jifeng Feng, Ying Cheng, Li Xiao, Qingyuan Zhang, Wensheng Qiu, Binghe Xu, Rui‐Hua Xu, Bo Shen, Zhiguo Luo, Xiaodong Xie, Jianhua Chang, Mengzhao Wang, Yufu Li, Yue-Rong Shuang, Zuoxing Niu, Бо Лю, Jun Zhang, Li Zhang, Herui Yao, Conghua Xie, Huiqiang Huang, Wangjun Liao, Gongyan Chen, Xiaotian Zhang, Han‐Xiang An, Yanhong Deng, Ping Gong, Jianping Xiong, Qinghua Yao, Xin An, Cheng Chen, Yanxia Shi, Jialei Wang, Xiaohua Wang, Zhi‐Qiang Wang, Puyuan Xing, Sheng Yang, Chenfei Zhou
S2764796312. 202095 CitationsOPEN ACCESS
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Qiao Li, Xiuwen Guan, Shanshan Chen, Zongbi Yi, Bo Lan, Puyuan Xing, Ying Fan, Jiayu Wang, Yang Luo, Peng Yuan, Ruigang Cai, Pin Zhang, Qing Li, Dafang Zhong, Yifan Zhang, Jianjun Zou, Xiaoyu Zhu, Fei Ma, Binghe Xu
Clinical Cancer Research. 201993 Citations
Related on ScholarIQ
Chinese Academy of Medical Sciences & Peking Union Medical College
Institution
Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
Paper
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
Paper
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
Paper
Current management of chemotherapy-induced neutropenia in adults: key points and new challenges
Paper
Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial
Paper